Privately-held US generic drugmaker Breckenridge Pharmaceutical has filed an Abbreviated New Drug Application with the US Food and drug administration, with a Paragraph IV certification for cabazitaxel solution; IV (infusion), a generic version of French pharma major Sanofi’s (Euronext: SAN) cancer drug Jevtana.
On January 14, 2015, Sanofi filed a Paragraph IV law suit against Breckenridge in the US District Court for the District of New Jersey. Breckenridge filed its Paragraph IV ANDA on the first-possible submission date and expects to be entitled to 180-day exclusivity. The ANDA was developed and will be manufactured by Breckenridge's partner, Natco Pharma.
Jevtana is a prescription drug that is indicated to treat prostate cancer. It generated US sales of $120.2 million for the 12-month period ending November 2014, based on industry sales data, quoted by Breckenridge. Globally, Jevtana sales reached 273 million euros ($310 million) in 2014, Sanofi reported earlier this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze